The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
Following the CE-IVD marking, Bruker launched the two products, the multiplex real-time PCR-based Fungiplex Candida assay and the Micronaut-AM test plate.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The infectious disease diagnostics firm secured eight new contracts covering 18 hospital in the US and Europe during the fourth quarter.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The AmpiProbe Candidiasis test identifies five common species of Candida bacteria from a vaginal swab, and is the third test from Enzo to be approved in NY state.
The PCR-based panel tests for the pathogens that cause three types of gynecological infection: bacterial vaginosis, candidiasis, and trichomoniasis.
The Scottish firm's product pipeline includes an identification test for bacterial gastroenteritis and genes for Carbapenem resistance.
The Associated Press reports that gene-edited food may soon be for sale.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.